Baseline Inflammatory Environment
COYA 301 plays a key role in the development, expansion, activity, and survival of Tregs
Menu
Dr. Shimon Sakaguchi, a member of our Scientific Advisory Board, discovered Tregs in 1995.
Dr. Stanley Appel, the Chair of our Scientific Advisory Board, and the research team at Houston Methodist Hospital leveraged this discovery by developing transformative therapies enhancing the immunomodulatory function of Tregs.
Tregs are a type of lymphocyte that modulate the body’s immune response.
The main functions of Tregs are:
Anti-inflammatory
Healthy Treg Cells
Pro-inflammatory Cells
and Cytokines
Tregs are important anti-inflammatory immune cells involved in homeostasis. Tregs act on multiple immune cells to down-regulate the release of pro-inflammatory cytokines.
Dysfunctional Tregs and Reduced Healthy Tregs
Pro-inflammatory Cells
and Cytokines
When Tregs become dysfunctional, a cytokine-mediated inflammatory state can arise leading to neurodegenerative, autoimmune, and metabolic diseases.
Synergistic enhancement of Treg function and depletion of effector
T cells and macrophages to further decrease inflammation.
COYA 302 is an investigational product candidate not yet approved by the US Food and Drug Administration.
Baseline Inflammatory Environment
COYA 301 will be supplied in a pre-filled syringe for subcutaneous injection.
COYA 301 is an investigational product candidate not yet approved by the US Food and Drug Administration.
Exosomes derived from Tregs, one of the most prominent anti-inflammatory and neuroprotective cell types.
COYA 201 is an investigational product candidate not yet approved by the US Food and Drug Administration.
Coya Therapeutics has licensed a proprietary platform for exosome polymer hybrids that allows the exosome to target proteins of interest while delivering drugs and/or cargo.
COYA 206 is an investigational product candidate not yet approved by the US Food and Drug Administration.
Expanded suppressive Tregs reduce neuroinflammation.
Phase 2a Study
Received Orphan Drug Designation
Ex Vivo Expansion
& Conversion
Cryopreservation &
Long-term Stability
Phase 2a Study
Received Orphan Drug Designation
COYA 101 is an investigational product candidate not yet approved by the US Food and Drug Administration.
We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. We are currently developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Links
